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Increasingly more psychiatric research studies use whole genome sequencing or whole
exome sequencing. Consequently, researchers face difficult questions, such as which
genomic findings to return to research participants and how. This study aims to gain
more knowledge on the attitudes among potential research participants and health
professionals toward receiving pertinent and incidental findings. A cross-sectional
online survey was developed to investigate the attitudes among research participants
toward receiving genomic findings. A total of 2,637 stakeholders responded: 241
persons with mental disorders, 671 relatives, 1,623 blood donors, 74 psychiatrists, and
28 clinical geneticists. Stakeholderswantedboth pertinent findings (95%) and incidental
findings (91%) to bemade available for research participants. Themajority (77%) stated
that researchers should not actively search for incidental findings. Persons with mental
disorders and relativeswere generallymorepositive about receiving any kindof findings
than clinical geneticists and psychiatrists. Compared with blood donors, persons with
mental disorders reported to be more positive about receiving raw genomic data and
information that is not of serious health importance.Psychiatrists andclinical geneticists
were less positive about receiving genomic findings compared with blood donors. The
attitudes toward receiving findings were very positive. Stakeholders were willing to
refrain from receiving incidental information if it could compromise the research. Our
results suggest that research participants consider themselves as altruistic participants.
This study offers valuable insight, whichmay inform future programs aiming to develop
new strategies to target issues relating to the return of findings in genomic research.
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1 | INTRODUCTION
Increasingly more research studies are based on genome sequencing
(whole genome sequencing or whole exome sequencing). Researchers
consequently face difficult questions, such as which genomic results to
return to research participants and how. In recent years, a debate has
evolved as to whether pertinent and incidental findings should be
returned andwhether the genetic researcher has a duty to inform about
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2017 The Authors. American Journal of Medical Genetics Part A Published by Published by Wiley Periodicals, Inc.
Am J Med Genet. 2017;173A:2649–2658. wileyonlinelibrary.com/journal/ajmga | 2649
individual genetic research results (Christenhusz, Devriendt, & Dierickx,
2013; McGuire & Lupski, 2010; Parens, Appelbaum, & Chung, 2013;
Ryan, De Vries, Uhlmann, Roberts, & Gornick, 2017; Solberg &
Steinsbekk, 2012; Steinsbekk & Solberg, 2012; Viberg, Segerdahl,
Langenskiöld, & Hansson, 2015; Wolf, 2012).
Genomic research potentially provides clinical information about
the current and future health of the research participant, and a result
with no interest for the research study could still be important for the
research participant. The standard practice in genetic research has
been not to give participants access to their personal sequencing data.
The research participants are seen as altruistic individuals, who do not
expect to derive any personal health benefits from participating, and
researchers do not analyze the entire genome for all possible risk
variants for any disorder (Kaye et al., 2014; McCann, Campbell, &
Entwistle, 2010). Rather, researchers restrict their analyze to the
variants associated with the disorder that is the focus of their study.
The American College ofMedical Genetics and Genomics (ACMG)
recommends that 59 specified pathogenic mutations (incidental
findings) should be searched for each time a clinical genome
sequencing is done, regardless of the indication for ordering the
clinical sequencing (ACMG Board of Directors, 2015; Green et al.,
2013; Kalia et al., 2017). In the research setting, the same variants may
also be identified and the ACMG's recommendations are thus relevant
to discuss among researchers because this specific genomic informa-
tion is medically actionable. However, when sequencing is considered
in the research setting, researchers have expressed concern that the
delivery of results at the individual level may risk to divert resources,
slow down the science, place a considerable burden on researchers,
and yet may have only limited benefit to the research participants
(Gliwa & Berkman, 2013; Wolf, 2012).
In the last few years, a strong interest has been taken in the
identification of the causes of mental disorders by studying genetic
factors using sequencing approaches (Merico et al., 2015; Yu et al.,
2013). Great hopes are attached to these technologies that may help
identify rare variants related to development of mental disorders and
introduce new, more effective methods of medical treatment (Cirulli &
Goldstein, 2010; Rabbani, Tekin, & Mahdieh, 2014).
Although the attitudes toward the return of pertinent and
incidental findings vary among experts, it is relevant to discuss the
attitudes among potential research participants and health profes-
sionals by exploring their views on the use of genomic research and
their expectations to forming part of genomic research. It is especially
important to explore the attitudes among relevant stakeholders in
psychiatric genomic research as individuals withmental disorders are a
vulnerable group, who may be subjected to stigmatization from
genomic research. Yet, at the same time, they also have the potential
benefit that discovering genetic causes of mental disorder may
alleviate self-blame and shame (Phelan, 2002).
Several previous studies have focused on the attitudes toward the
return of pertinent and incidental findings (Bui, Anderson, Kassem, &
McMahon, 2014; Klitzman et al., 2013; Middleton et al., 2016; Yu,
Harrell, Jamal, Tabor, & Bamshad, 2014). Yet, to our knowledge,
no larger studies have investigated the attitudes of patients, relatives,
and health professionals in psychiatry and genetics toward the
return of pertinent and incidental findings in genome sequencing in
the research setting.
Therefore, we designed a study to explore the attitudes among
five different groups of such stakeholders: persons with mental
disorders, relatives, healthy individuals (blood donors), psychiatrists,
and clinical geneticists. In this article, we analyze attitudes toward the
sharing of raw genomic data, pertinent and incidental findings, and the
duty of the researchers to search for incidental findings.
2 | MATERIALS AND METHODS
2.1 | Qualitative interviews
Semi-structured interviews were conducted to explore the attitudes
toward ethical issues regarding genome sequencing among health
professionals engaged in genomic sequencing and among potential
research participants. Six interviews were conducted with genetic
researchers from Iceland and Denmark, including the Faroe Islands,
three interviews were conducted with patients with schizophrenia,
and four focus group interviews were conducted with clinical
geneticists, relatives to individuals with ADHD, individuals with
ADHD, blood donors from The Danish Blood Donor Study (Pedersen
et al., 2012; The Danish Blood Donor Study, 2016).
All interviews were conducted from December 5, 2012 to
December 11, 2013. Each interview lasted between 30 and 90 min.
All interviews were audio-recorded, transcribed verbatim, and coded in
NVivo (QSR International.Daresbury,Cheshire,UnitedKingdom,2017).
2.2 | The survey
This study was carried out as a cross-sectional study based on survey
data. The survey was developed to explore attitudes toward the use of
genome sequencing in research. The survey was web-based
(https://svaros.dk/holdning) and a modified version of the web-based
survey (www.genomethics.org) developed at the Wellcome Trust
Sanger Institute in Cambridge, United Kingdom (Middleton, Bragin,
Morley, & Parker, 2013; Middleton, Bragin, & Parker, 2014; Middleton
et al., 2015, 2016; Middleton, Parker, Wright, Bragin, & Hurles, 2013).
The development process and validation techniques of the English
survey are described elsewhere (Middleton, Bragin et al., 2013). Ten
video films with subtitles and voice-over were used to explain the
survey background and to illustrate the ethical issues relating to nine
focus areas of the survey. The survey, the voice-over, and the subtitles
for the video films were translated into Danish using the cross-cultural
adaption process described by (Beaton, Bombardier, Guillemin, &
Ferraz, 2000).
On the basis of the information in the qualitative interviews, we
modified the Danish version of the survey to also include items about:
1) informed consent; 2) inclusion of children in genomic research; and
3) personal experience with mental disorders.
The final survey included a total of nine themes and focused on
attitudes toward: 1) sharing pertinent findings; 2) sharing incidental
2650 | SUNDBY ET AL.
findings; 3) receiving incidental findings in different categories of
severity and treatability; 4) sharing of raw genomic data; 5) the duty of
genomic researchers to search for incidental findings; 6) risk
perception; 7) filtering genomic data; 8) potential consenting
procedures for genomic research studies; and 9) children in genomic
research. The majority of items were responded to by dichotomous
answers and a “Don’t know” option. The survey also collected socio-
demographic information. In addition, the survey requested informa-
tion about personal and familial experience with mental disorders and
about prior personal experience with participation in genetic research,
genetic testing, or genomic sequencing.
A number of pilot tests of the survey were performed. After
each pilot test, the survey was revised in accordance with the
findings in the pilot testing. The first draft of the survey was pilot
tested in a small sample of genetic researchers (n = 11) in April
2014. The second draft was tested in a group of blood donors from
the Danish Blood Donor Study (Pedersen et al., 2012; The Danish
Blood Donor Study, 2016) and participants in the qualitative
interviews (n = 54) in May 2014. It took approximately 23 min
to complete the final survey. Responses to the survey were
anonymous.
2.3 | Recruitment of stakeholders
Stakeholders were identified and recruited: 1) persons with mental
disorders (who are potential cases in psychiatric genomic research); 2)
relatives to individuals with mental disorders (who are potential
controls in psychiatric genomic research and also potential stake-
holders who can benefit from both pertinent and incidental findings);
3) blood donors from theDanish BloodDonor Study (who are potential
healthy controls in genomic research) (Pedersen et al., 2012; The
Danish Blood Donor Study, 2016); 4) clinical geneticists (who in their
clinical work conduct, analyze, return, and explain genomic data to
patients and their relatives, and who may have to validate sequencing
findings obtained in the research context); and 5) psychiatrists (who
diagnose, treat, and care for people withmental disorders). As genomic
analyze is incorporated in both research and clinical practise, it is
imperative to explore the attitudes of clinical geneticists and
psychiatrist as their attitudes may affect their advice to patients,
relatives, and healthy controls.
Stakeholders were recruited via direct invitations by email,
paper flyers at psychiatric hospitals, invitations posted in an ADHD
Facebook group, and links at the homepages of the Danish
Psychiatric Association, the Danish Society of Medical Genetics,
and for user groups of psychiatric patients and their relatives.
The data collection began on 12 August 2014 and ended on 17
April 2015.
2.4 | Ethical considerations
The project was approved by the Danish Data Protection Agency (file
no. 2007-58-015). The Committee on Health Research Ethics in the
Capital Region of Denmark reviewed the project description and
concluded that the study did not require ethical approval
(file no. H-4_2013_FSP-051). As all data are based on anonymous
interviews and survey information, no other ethical clearance is
required for this type of study according to Danish law.
2.5 | Statistical analyze
The analyze of the data was carried out using SAS® 9.3 (SAS Institute
Inc., Cary, USA, 2017). Descriptive statistics were used to characterize
the study sample. Unadjusted associations between items and
stakeholder groups were estimated using χ2 tests. Binary logistic
regression models were used to estimate these associations adjusted
for gender, age, level of education,marital status, and parenthood, with
99% confidence intervals (CI). A p-value of 0.01 was chosen to denote
statistical significance and minimize Type 1 errors from multiple
testing. Blood donors were chosen as reference group because they
are healthy individuals and therefore potential healthy controls in
genomic research. “Don’t know” answers from respondents were
omitted from the corresponding binary logistic regression models.
3 | RESULTS
3.1 | Sample characteristics
The distribution of socio-demographic characteristics is presented by
stakeholder group in Table 1. The survey was completed by 2,637
individuals: 241 persons with mental disorders, 671 relatives, 1,623
blood donors, 74 psychiatrists, and 28 clinical geneticists. There were
more females (53%) than males (47%), except among blood donors. As
shown in Table 1, the majority of the stakeholders were aged 41–60
years and had a medium higher education (31%) or a long higher
education (34%). The majority of the sample was married/cohabiting
(67%) and had no children (53%).
3.2 | Attitudes toward receiving pertinent and
incidental findings
Table 2 shows attitudes toward receiving pertinent and
incidental findings. A majority (95%) of the stakeholders had a
positive attitude toward the sharing of pertinent findings. A total
of 91% wanted incidental findings from genomic studies to be
made available to research participants, although psychiatrists
(74%) and clinical geneticists (86%) were less likely to hold this
view (Table 2).
In total, 77% of the stakeholders thought that genomic
researchers should not actively search for incidental findings. Clinical
geneticists (96%) and psychiatrists (91%) were significantly more
negative than the three other groups. In total, 15% of the stakeholders
supported that genomic researchers should actively search for
incidental findings. Of the 15%, 38% agreed that genomic researchers
should actively search for incidental findings, even if it would be
expensive and time-consuming (Table 2).
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3.3 | Attitudes toward receiving different categories
of findings
To gain a deeper understanding of attitudes toward receiving findings,
we asked stakeholders which kind of findings they would be interested
in receiving (Tables 3 and 4). Table 3 provides the unadjusted
associations between statements and stakeholder groups, and Table 4
provides the adjusted and significant associations.
Most stakeholders (68%) did not want to receive all their raw
genomic data. More clinical geneticists (85%) had this view (Table 3).
Significant differences existed between the groups: persons with
mental disorders were more likely to agree than blood donors
(OR = 1.962) (Table 4).
In relation to the questions about receiving findings at different
levels of severity and treatability of a disorder, a total of 54%
of the stakeholders would prefer to receive information about
TABLE 1 Distribution of socio-demographic characteristics for the five stakeholders groups
Persons with mental
disordersa (n = 241)
Relativesa
(n = 671)
Blood donorsa
(n = 1,623)
Psychiatristsa
(n = 74)
Clinical
geneticists
(n = 28)
Totala
(n = 2,637)
% (n) % (n) % (n) % (n) % (n) % (n)
Gender
Female 75 (180) 55 (372) 47 (769) 58 (42) 86 (24) 53 (1,387)
Male 25 (61) 45 (299) 53 (851) 42 (31) 14 (4) 47 (1,246)
Age groups
20–30 years 13 (31) 15 (97) 11 (176) 3 (2) 0 (0) 12 (306)
31–40 years 20 (48) 21 (139) 20 (327) 33 (24) 25 (7) 21 (545)
41–50 years 27.5 (66) 25 (171) 27 (437) 16 (12) 28 (8) 26 (694)
51–60 years 27.5 (66) 26 (177) 26 (417) 20 (15) 36 (10) 26 (685)
61–70 years 11 (26) 12 (79) 15 (249) 27 (20) 11 (3) 14 (377)
71–76 years 1 (3) 1 (6) 1 (14) 1 (1) 0 (0) 1 (24)
Educational level
None 5 (12) 2 (13) 2 (26) 0 (0) 0 (0) 2 (51)
One or more short
courses
4 (10) 2 (16) 2 (25) 0 (0) 0 (0) 2 (51)
Skilled worker in craft,
office, etc.
16 (39) 15 (102) 17 (276) 0 (0) 0 (0) 16 (417)
Short higher education
<3 years
15 (35) 13 (86) 10 (170) 0 (0) 0 (0) 11 (291)
Medium higher
education, 3–4 years
30 (72) 35 (232) 31 (502) 0 (0) 0 (0) 31 (806)
Long higher education,
>4 years
24 (58) 29 (196) 34 (554) 100 (74) 100 (28) 34 (910)
Other education 6 (14) 4 (25) 4 (70) 0 (0) 0 (0) 4 (109)
Marital status
Married/living together 57 (136) 62 (417) 70 (1,128) 79 (58) 82 (23) 67 (1,762)
Partnership 13 (30) 17 (116) 10 (161) 4 (3) 4 (1) 12 (311)
Divorced/separated 8 (20) 5 (34) 5 (79) 6 (4) 7 (2) 5 (139)
Widowed 2 (5) 1 (7) 1 (17) 3 (2) 0 (0) 1 (31)
Single 20 (49) 15 (97) 14 (236) 8 (6) 7 (2) 15 (390)
Children
0 57 (138) 52 (348) 54 (871) 53 (39) 36 (10) 53 (1,406)
1 16 (38) 18 (123) 18 (293) 14 (10) 18 (5) 18 (469)
2 21 (51) 22 (146) 22 (362) 20 (15) 21 (6) 22 (580)
3 5 (13) 6 (43) 5 (82) 8 (6) 25 (7) 6 (151)
4+ 1 (1) 2 (10) 1 (12) 5 (4) 0 (0) 1 (27)
an varies because of missing data.
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life-threatening conditions even if it cannot be prevented (Table 3).
Clinical geneticists were significant less likely to hold this view than
blood donors (OR = 0.312) (Table 4). A large majority of the
stakeholders (97%) were interested in receiving findings relating
to preventable life-threatening conditions (Table 3).
Fewer though, and still the majority (61%), would like to receive
information about a serious but not life-threatening condition that cannot
be prevented (Table 3). Clinical geneticists (37%) and psychiatrists (39%)
were less interested in receiving information about this type of condition
(Table 3). When we explored these results by stakeholder group,
psychiatristswere significant less likely thanblooddonors tobe interested
in receiving findings concerning a serious unpreventable condition
(OR =0.43) (Table 4). A total of 96% would prefer to receive information
about serious preventable conditions (Table 3).
As Table 3 shows, 68% of our stakeholders agreed with the survey
statement “I would like to receive information that is not immediately
relevant but could be useful later in life.” Psychiatrists were less likely
than blood donors to be interested in receiving not immediately
relevant information (OR = 0.46) (Table 4). In total, 64% of the
stakeholders would prefer not to receive “information that is uncertain
and cannot be interpreted at the moment” (Table 3).
When asked about receiving information that is not likely to be of
serious health importance, half of the stakeholders (50%) indicated
that they would not like to receive this information (Table 3). Persons
with mental disorders tended more likely to agree with this statement
than blood donors (OR = 1.51) (Table 4).
A total of 83% of the stakeholders would like to receive
information that could predict how they might respond to different
medications or drugs, and 87%preferred to know if they are carrier of a
condition that could be relevant to their children (Table 3).
Finally, we asked about their attitude toward receiving informa-
tion about ancestry: 74% of the persons with mental disorders, 72% of
TABLE 2 Attitudes toward return of pertinenta and incidentalb findings
Persons with
mental disordersc
(n = 241)
Relativesc
(n = 671)
Blood donorsc
(n = 1,623)
Psychiatrists
(n = 74)
Clinical geneticists
(n = 28)
Totalc
(n = 2,637)
% (n) % (n) % (n) % (n) % (n) % (n)
Do you think that pertinent findings from genomic studies should be made available to research participants?
Yes 96 (230) 95 (638) 95 (1,545) 89 (66) 93 (26) 95 (2,505)
No 4 (9) 4 (23) 4 (61) 7 (5) 3 (1) 4 (99)
Do not
know
1 (1) 1 (9) 1 (17) 4 (3) 3 (1) 1 (31)
χ2 = 10.40, df = 8, p-value = 0.24
Do you think that incidental findings from genomic studies should be made available to research participants?
Yes 95 (227) 91 (610) 91 (1,481) 74 (55) 86 (24) 91 (2,397)
No 3 (8) 6 (40) 7 (112) 20 (15) 7 (2) 7 (117)
Do not
know
2 (5) 3 (20) 2 (28) 6 (4) 7 (2) 2 (59)
χ2 = 37.57, df = 8, p-value = < 0.0001
Assuming research participants’ consent, do you think that genomic researchers should actively search for incidental findings that are not relevant to
the research study?
Yes 18 (44) 16 (110) 14 (223) 5 (4) 4 (1) 15 (382)
No 71 (170) 75 (500) 78 (1,264) 91 (67) 96 (27) 77 (2,028)
Do not
know
11 (25) 9 (61) 8 (135) 4 (3) 0 (0) 8 (224)
χ2 = 21.77, df = 8, p-value = 0.005
Actively searching for incidental findings that are not relevant to the research study is likely to be very expensive and time-consuming. This may mean
that the research is compromised. Given this caveat, do you still feel it is important for genomic researchers to actively search for incidental findings
that are not relevant to their research study?
Yes 55 (23) 41 (45) 31 (69) 100 (4) 100 (1) 38 (142)
No 36 (15) 39 (43) 45 (99) 0 (0) 0 (0) 41 (157)
Do not
know
9 (4) 20 (22) 24 (53) 0 (0) 0 (0) 21 (79)
χ2 = 19.03, df = 8, p-value = 0.014
aA result from a genetic test or genomic study which is directly relevant to the condition being investigated.
bA result from a genetic test or genomic study which is not directly related to the condition being explored.
cn varies because of missing data.
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TABLE 3 Attitudes toward receiving genomic information
Persons with mental
disordersa (n = 241)
Relativesa
(n = 671)
Blood donorsa
(n = 1,623)
Psychiatristsa
(n = 74)
Clinical geneticistsa
(n = 28)
Totala
(n = 2,637)
% (n) % (n) % (n) % (n) % (n) % (n)
If you were a research participant in a whole genome study, would you want to be able to receive all of your raw genomic data?
Yes 31 (75) 20 (136) 21 (341) 20 (15) 14 (4) 22 (571)
No 59 (141) 67 (450) 70 (1,134) 77 (57) 85 (24) 68 (1,806)
Do not
know
10 (23) 13 (84) 9 (145) 3 (2) 0 (0) 10 (254)
χ2 = 30.86, df = 8, p-value = 0.0001
I would like to know about life-threatening conditions that cannot be prevented
Yes 60 (141) 53 (344) 55 (874) 41 (28) 32 (9) 54 (1,396)
No 24 (55) 28 (186) 27 (435) 39 (27) 61 (17) 28 (720)
Do not
know
16 (37) 19 (121) 18 (277) 20 (14) 7 (2) 18 (451)
χ2 = 25.40, df = 8, p-value = 0.001
I would like to know about life-threatening conditions that can be prevented
Yes 99 (237) 97 (647) 97 (1,572) 93 (68) 96 (27) 97 (2,551)
No 0.4 (1) 2 (12) 2 (35) 6 (4) 4 (1) 2 (53)
Do not
know
0.4 (1) 1 (10) 1 (13) 1 (1) 0 (0) 1 (25)
χ2 = 11.84, df = 8, p-value = 0.16
I would like to know about serious (but not life-threatening) conditions that cannot be prevented
Yes 68 (158) 60 (398) 62 (997) 39 (28) 37 (10) 61 (1,591)
No 23 (53) 28 (182) 26 (417) 45 (32) 56 (15) 27 (699)
Do not
know
9 (22) 12 (78) 12 (195) 16 (11) 7 (2) 12 (308)
χ2 = 31.58, df = 8, p-value = 0.0001
I would like to know about serious (but not life-threatening) conditions that can be prevented
Yes 98 (234) 96 (642) 96 (1,548) 89 (65) 96 (27) 96 (2,516)
No 2 (4) 3 (16) 3 (50) 8 (6) 4 (1) 3 (77)
Do not
know
0.4 (1) 1 (8) 1 (18) 3 (2) 0 (0) 1 (29)
χ2 = 12.68, df = 8, p-value = 0.12
I would like to receive information that could predict how I might respond to different medications or drugs (e.g., cholesterol-lowering drugs, anti-
depressants)
Yes 87 (205) 82 (540) 83 (1,316) 82 (58) 85 (23) 83 (2,142)
No 8 (20) 11 (70) 11 (117) 14 (10) 11 (3) 11 (280)
Do not
know
5 (12) 7 (44) 6 (95) 4 (3) 4 (1) 6 (155)
χ2 = 4.02, df = 8, p-value = 0.86
I would like to receive information that could tell me if I am a carrier of a condition that could be relevant to my children
Yes 92 (219) 87 (581) 87 (1,414) 77 (57) 93 (26) 87 (2,297)
No 5 (12) 8 (51) 8 (127) 12 (9) 7 (2) 8 (201)
Do not
know
3 (8) 6 (38) 5 (77) 11 (8) 0 (0) 5 (131)
χ2 = 14.28, df = 8, p-value = 0.07
I would like to receive information that is not immediately relevant but could be useful later in life (e.g., very late onset cancer or predisposition to
strokes)
(Continues)
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the relatives, 69% of the blood donors, 51% of the psychiatrists, and
39% of the clinical geneticists were interested in receiving this type of
information (Table 3). Significant differences were found between
stakeholder groups; psychiatrists (OR = 0.48) and clinical geneticists
(OR = 0.28) were less likely than blood donors to believe that
information of ancestry should be shared (Table 4).
4 | DISCUSSION
Through an online survey, we asked the stakeholders to imagine that
they were participating in a whole genome sequencing research study
and presented them to several hypothetical scenarios. Our analyze
show that a majority in the stakeholder groups would like to receive
health-related individual level findings, depending on the severity and
treatability of the condition, information about drug response and
carrier conditions that could be relevant to their children. The access to
this kind of information may provide the stakeholders with a better
understanding of their ownhealth andmake it easier to take preventive
steps. The research participants thus see themselves as potential
patients, who might benefit from the research. We also found that
genomic information about ancestry was more important to persons
with mental disorders, relatives, and blood donors than to clinical
geneticists and psychiatrists. A previous study found that the primary
motivation for accessing DNA ancestry test information was educa-
tional advancement, interest in genealogical research, and entertain-
ment. Very few of the respondents who had experience with DNA
ancestry testing indicated that medical research was a motivational
factor for the test (Wagner&Weiss, 2012). For the health professionals
in our study, the low interest in ancestry may reflect that they do not
believe that this kind of information is sufficiently important for the
health to be returned to the participants by the researchers.
Despite interest in findings, changes in health behavior are not
likely to be realized. A Cochrane review by (Marteau et al., 2010)
explored if risk estimates derived from a genetic test could motivate
people to change their behavior. They found no evidence that
receiving DNA-based test results motivated people to change their
behavior (Marteau et al., 2010). Even if the stakeholders would like to
receive individual results and believe that theywill find the information
useful, they may not actually act on it.
However, only 22% of the stakeholders were interested in
receiving their own raw data, although persons with mental disorders
TABLE 3 (Continued)
Persons with mental
disordersa (n = 241)
Relativesa
(n = 671)
Blood donorsa
(n = 1,623)
Psychiatristsa
(n = 74)
Clinical geneticistsa
(n = 28)
Totala
(n = 2,637)
% (n) % (n) % (n) % (n) % (n) % (n)
Yes 69 (166) 66 (439) 69 (1,118) 53 (39) 59 (16) 68 (1,178)
No 18 (44) 24 (162) 23 (368) 36 (27) 26 (7) 23 (608)
Do not
know
13 (30) 10 (65) 8 (134) 11 (8) 15 (134) 9 (241)
χ2 = 17.98, df = 8, p-value = 0.021
I would like to receive information that is uncertain and cannot be interpreted at the moment
Yes 26 (63) 22 (147) 24 (382) 16 (12) 10 (3) 23 (607)
No 58 (138) 65 (427) 63 (1,028) 73 (54) 78 (22) 64 (1,669)
Do not
know
16 (37) 13 (87) 13 (207) 11 (8) 12 (207) 13 (342)
χ2 = 9.82, df = 8, p-value = 0.28
I would like to receive information that is not likely to be of serious health importance (e.g., mild eyesight problems)
Yes 52 (125) 40 (266) 43 (701) 28 (21) 21 (6) 43 (1,119)
No 42 (100) 51 (334) 50 (802) 65 (48) 79 (22) 50 (1,306)
Do not
know
6 (14) 9 (62) 7 (112) 7 (5) 0 (0) 7 (193)
χ2 = 30.77, df = 8, p-value = 0.0002
I would like to receive information that tell me about my ancestry
Yes 74 (178) 72 (478) 69 (1,122) 51 (38) 39 (11) 70 (1,827)
No 17 (41) 19 (130) 23 (373) 37 (27) 54 (15) 22 (586)
Do not
know
9 (21) 9 (59) 8 (123) 12 (9) 7 (2) 8 (214)
χ2 = 35.63, df = 8, p-value = < 0.0001
Numbers in bold are significant at 1%.
an varies because of missing data.
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took a more positive approach than blood donors. Middleton et al.
(2015) found thatmost genomic researchers (68%), non-genetic health
professionals (57%), and the general public (61%) were interested in
receiving their own raw sequence data (Middleton et al., 2015). The
raw sequencing data do not seem to have the same personal utility for
the Danish stakeholder groups in our study compared with the non-
Danish stakeholder groups in the study byMiddleton et al (participants
in the Middleton study were from 75 countries across the world)
(Middleton et al., 2015). Our data suggest that the stakeholders
perceive the raw genomic data as less interpretable and more complex
than individual level results.
Previous studies have discussed whether researchers have
specific responsibilities to communicate individual research results
to research participants (Gliwa & Berkman, 2013; Knoppers, Joly,
Simard, & Durocher, 2006). Our study shows that people would
generally like to receive incidental findings, but they do not expect this
information to be returned at all costs. This indicates that stakeholders
can be characterized as altruistic participants who believe that the
primary duty of the researchers is to do research and that their own
duty is to help others. The stakeholders do not expect research to be
compromised by the researchers’ active search for incidental findings,
even if such findings could be of interest to the research participant.
We found consistent differences in the attitudes between
potential participants in research and the stakeholders who deal
with genomic data in their clinical work, for example, explaining
findings to patients and relatives or providing care for people with
mental disorders. For potential participants in research, there may be a
clinical motivation to participate as they may gain an opportunity to
receive a diagnosis, help identify more effective methods of medical
treatment, and obtain more clinical knowledge about their own health.
A study by Jallinoja and Aro (2000) found that the individuals in the
Finnish population with the highest level of knowledge of genetics
were both more enthusiastic and yet more sceptical toward genetic
testing than the individuals with the lowest level of knowledge. A study
by (Laegsgaard, Kristensen, & Mors, 2009) showed that persons with
an anxiety disorder had a higher knowledge score of mental illness and
genetics than persons with depression. However, significantly more
persons with depression than persons with anxiety have intentions
toward undergoing psychiatric genetic testing. Because of the
education and professional training of clinical geneticists and
psychiatrists, they are much more likely to understand this type of
data, but they are also least interested in receiving such information
and appear to take a more conservative approach than persons with
mental disorders. The health professionals must explain the findings to
patients, but theymust also provide help and support if the patients are
unable to cope with the findings. The implication of this is that health
professionals, particularly psychiatrists, must have knowledge of
health-related areas outside their field of expertise. The less positive
attitudes among health professionals could be caused by inability to
cope with the workload and from lack of skills. Some health
professionals are familiar with returning findings and may have more
concerns about the clinical validity and utility of the genomic findings
than patients do.
TABLE 4 Attitudes toward receiving genomic information with
blood donors as reference group: adjusteda results
OR 99% CI p-value
If you were a research participant in a whole genome study, would
you want to be able to receive all of your raw genomic data?
Persons with mental disorders 1.96 1.28–3.00 < 0.0001
Relatives 1.04 0.76–1.41 0.75
Psychiatrists 0.85 0.38–1.90 0.61
Clinical geneticists 0.66 0.16–2.77 0.46
p-value = 0.001
I would like to know about life-threatening conditions that cannot be
prevented.
Persons with mental disorders 1.34 0.85–2.10 0.10
Relatives 0.94 0.70–1.25 0.56
Psychiatrists 0.54 0.25–1.13 0.032
Clinical geneticists 0.31 0.10–0.92 0.006
p-value = 0.004
I would like to know about serious (but not life-threatening)
conditions that cannot be prevented.
Persons with mental disorders 1.32 0.85–2.08 0.11
Relatives 0.94 0.71–1.25 0.58
Psychiatrists 0.43 0.21–0.88 0.003
Clinical geneticists 0.38 0.13–1.13 0.02
p-value = 0.002
I would like to receive information that is not immediately relevant
but could be useful later in life. (e.g., very late onset cancer or
predisposition to strokes)
Persons with mental disorders 1.29 0.80–2.08 0.17
Relatives 0.90 0.68–1.21 0.37
Psychiatrists 0.46 0.23–0.93 0.004
Clinical geneticists 0.82 0.24–2.76 0.67
p-value = 0.02
I would like to receive information that is not likely to be of serious
health importance (e.g., mild eyesight problems)
Persons with mental disorders 1.51 1.03–2.22 0.01
Relatives 0.94 0.73–1.21 0.52
Psychiatrists 0.53 0.26–1.10 0.03
Clinical geneticists 0.37 0.11–1.27 0.04
p-value = 0.001
I would like to receive information that tell me about my ancestry
Persons with mental disorders 1.47 0.90–2.39 0.04
Relatives 1.26 0.93–1.71 0.05
Psychiatrists 0.48 0.24–0.97 0.007
Clinical geneticists 0.28 0.10–0.83 0.002
p-value = < 0.0001
Numbers in bold are significant at 1%.
aAdjusted for: gender, age, educational level, marital status, and
parenthood.
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5 | LIMITATIONS
Stakeholders were recruited using an online advertisement. This
required the individuals to have familiarity with computers, laptops,
tablets, or smartphones, and this approach excluded anyone without
those skills or such access. Advertisements were placed on websites,
and participant ascertainment would thus tend to favor the more
proactive and information-seeking stakeholders. Stakeholders were
recruited through a diversity of sources, and all stakeholders
volunteered. Therefore, it is likely that they are a more homogeneous
group and more in favor of genomic research than others who did not
respond to the survey.
The design of the online survey did not provide us with any details
on the non-response rate. According to the Danish Health Data
Authority, there were 36 clinical geneticists and 1,125 psychiatrists in
total in Denmark as of December 31, 2013 (Sundhedsdatastyrelsen,
2016). Almost all clinical geneticists responded to the survey, whereas
only very few psychiatrists responded. According to Galea and Tracy
(2007) low interest in participating could arise if the potential
participants are much more likely to take part in a study focusing on
an issue salient to the participant's life. One hypothesis explaining the
low response rate among psychiatrists could be that there is a relation
between outcome of interest and likelihood to participate.
Another limitation of this study is that we included persons with
different mental disorders as one category. Different mental disorders
involve different levels of severity, and attitudes may differ depending
on diagnosis. This topic remains to be investigated in future studies.
This study provides new insight into the attitudes among relevant
stakeholder groups in psychiatric genomic research toward receiving
genomic information in a hypothetical research scenario. The
recruitment strategies meant that it would not be possible for the
final sample to be representative. Although the study provides
evidence about attitudes toward hypothetical scenarios and shows
that the majority of the stakeholders reported to have a positive
attitude toward receiving genomic information, it does not mean that
they would want to receive the information in a real-life situation.
6 | CONCLUSION
We studied the relationship between five groups of selected stake-
holders in psychiatry and their attitudes toward receiving genomic
research findings. Overall, the attitudes toward the survey statements
about receiving findings were very positive. Persons with mental
disorders and relativeswere generallymorepositive about receiving any
kind of findings than clinical geneticist and psychiatrists. Comparedwith
blood donors, persons with mental disorders reported to be more
positive about receiving rawgenomic data and information that is not of
serioushealth importance.Psychiatrists andclinical geneticistswere less
positive about receiving genomic findings compared with blood donors.
An important finding is the general support to the return of incidental
findings to research participants. Additionally, the stakeholders did not
expect researchers to actively search for incidental findings. Most
importantly, stakeholders were generally willing to refrain from
receiving personal information if it could compromise the research.
Our results confirm the assumption that research participants consider
themselves as altruistic participants.
This study offers valuable insights, which may inform future
programs aiming to develop new strategies to target issues relating to
the return of results in genomic research.
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